The CONSENSE project is developing a new sensor technology suitable for measuring biomolecules important for monitoring disease status and treatment efficacy. A generic technology that enables the continuous measurement of a wide range of biomolecular parameters could revolutionise patient monitoring and enable truly personalised therapy with better outcomes.
CONSENSE brings together internationally leading pioneers in biomolecular switch engineering with research groups that have an excellent track record in biosensor development using advanced optical approaches, including two high-tech companies that have spun out from these groups. The consortium is completed by a strong network of partner industries and organisations, including four large medical technology companies, clinical experts, and six SMEs providing specific technical expertise and training.
Follow up: Consense meets at SensUs 2023!
Hey everyone! In the vibrant tech hub of Europe, Eindhoven, CONSENSE marks the beginning of September with an annual
CONSENSE ESRs present their work at SensUs 2023
Curious to find out about the latest findings and research done within CONSENSE? Then meet us at SensUs 2023!
CONSENSE presents at BIOSENSORS 2023!
A month ago, Andris Jeminejs and Emily Tsang attended the 33rd Anniversary World Congress on Biosensors in Busan, South